UNSPSC 51433933: Elgodipine hydrochloride

This classification denotes a calcium channel blocker with the molecular formula C29H33FN2O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MIR106H7SI, chemically known as 2-((p-fluorobenzyl)methylamino)ethyl isopropyl (+/-)- 1,4-dihydro-2,6-dimethyl-4-(2,3-(methylenedioxy)phenyl)-3,5-pyridinedicarboxylate hydrochloride, but more generally known as elgodipine hydrochloride, which bears US NIH Compound Identifier 60701.

European Medicines Agency schedules elgodipine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06484MIG. Most nations, for tariff purposes, schedule elgodipine hydrochloride under HS 29349990. SMILES: CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2CCCC3C2OCO3)C(=O)OCCN(C)CC4CCC(CC4)F.CL.

UNSPSC 51433933 Elgodipine hydrochloride is a Commodity code covering a specific pharmaceutical active ingredient used in cardiovascular medications. State and local governments procure this product primarily through emergency medical services (EMS) and health agency channels as part of Advanced Life Support medication programs and pharmacy benefit supply chains. The solicitations below show that buying bodies treat this code as part of broader pharmaceutical procurement frameworks rather than isolated single-molecule acquisitions—the work involves supplying finished dosage forms (tablets, vials, injections) containing the active ingredient to emergency responders, hospital systems, and state health programs, bundled with regulatory compliance (Safety Data Sheets, cGMP certification, Drug Supply Chain Security Act compliance), shelf-life warranties, and delivery commitments.

Recent activity spans fire-rescue services, state health commissions, and multistate cooperative purchasing alliances. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (IFB No. 26P00188, due April 8, 2026) for Tampa Fire Rescue, specifying four medication line items alongside elgodipine-derivative products, with a $40,000 estimated contract value and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013, posted April 3, 2026) to explore Direct-to-Manufacturer Prescriptions capabilities as part of a Therapeutic Pharmacy Initiative, signaling state-level consolidation of pharmaceutical contracting outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (administered by the Minnesota Department of Administration) released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and participating jurisdictions, requiring vendor compliance with cGMP, DSCSA, and specified wholesaler relationships. These opportunities cluster in Florida, Texas, and the upper Midwest, reflecting regional variation in EMS procurement timing and state-level pharmacy benefit consolidation initiatives.